Picard Medical (PMI)
Provides total artificial heart systems and external drivers for bridge-to-transplant care.
Something off on this page? Send us feedback.
Sells the SynCardia Total Artificial Heart and external drivers to transplant centers, earning mainly from implant kits plus driver rentals, training, and certification. Commercial activity centers on a single bridge-to-transplant platform approved in the United States and Canada.
Produces the SynCardia Total Artificial Heart, a biventricular replacement approved in the United States and Canada as a bridge to transplant for patients with end-stage biventricular heart failure. Hospitals and transplant centers purchase implant kits; the company also rents the Freedom Driver for discharged patients and provides center training and certification.
Operates a direct North American sales and clinical-support team alongside international distributors, while manufacturing implants and drivers in Tucson. Its commercial platform combines approved implants with external pneumatic drivers, and it is developing the Emperor electromechanical architecture and driver upgrades. Revenue depends on transplant-center adoption, training, reimbursement, regulated manufacturing, and the approval status of the single platform.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $38.0K · Total debt $878.0K · Total assets $9.2M · Shareholders' equity $1.7M
- Revenue
- $3.0M
- Operating income
- −$4.6M
- Net income
- −$5.7M
No dividends on record.
| Institutions | 6.50% | 152.1K shares | |
|---|---|---|---|
| 40 holders · as of Jun 30, 2026 | |||
| Other | 93.50% | 2.19M shares | |
| remainder | |||
2.34M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (2.34M in the company's Sep 23, 2026 report, 2.06M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 2.15% | 2.52M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 1.83% | 2.14M | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 1.18% | 1.38M | as of Jun 30, 2026 |
Ieq Capital, LLCInstitution | 0.25% | 290,575 | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 0.15% | 172,381 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Abbott
Durable LVAD alternative in bridge-to-transplant support.
- Johnson & Johnson
Temporary percutaneous support in acute heart-failure care.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Picard Medical | $4.45 | +2.77% | $8.9M | — | — | 1.4 | +38.6% |
| Abbott | $103.64 | −0.09% | $179.49B | 33.4 | 17.9 | 3.9 | +13.0% |
| Johnson & Johnson | $271.17 | +0.74% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| Median | 32.3 | 20.4 | 5.2 | +9.8% |